Larissa Fonseca

Ms. Larissa Fonseca

Centro Universitário SENAI-CIMATEC, Salvador, Bahia, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in Heliyon
Verified
Journal Article
Open access
MSMatheus Carmo dos Santos
Matheus Carmo dos Santos
ASAna Clara Cerqueira Silva
Ana Clara Cerqueira Silva
CTCarine dos Reis Teixeira
Carine dos Reis Teixeira
FPFilipe Pinheiro Macedo Prazeres
Filipe Pinheiro Macedo Prazeres
RSRosângela Fernandes dos Santos
Rosângela Fernandes dos Santos
Bruna MachadoBruna Machado
Bruna Machado
A focus on water quality has intensified globally, considering its critical role in sustaining life and ecosystems. Wastewater, reflecting societal development, profoundly impacts public health. Wastewater-based epidemiology (WBE) has emerged as a surveillance tool for detecting outbreaks early, monitoring infectious disease trends, and providing real-time insights, particularly in vulnerable communities. WBE aids in tracking pathogens, including viruses, in sewage, offering a comprehensive understanding of community health and lifestyle habits. With the rise in global COVID-19 cases, WBE has gained prominence, aiding in monitoring SARS-CoV-2 levels worldwide. Despite advancements in water treatment, poorly treated wastewater discharge remains a threat, amplifying the spread of water-, sanitation-, and hygiene (WaSH)-related diseases. WBE, serving as complementary surveillance, is pivotal for monitoring community-level viral infections. However, there is untapped potential for WBE to expand its role in public health surveillance. This review emphasizes the importance of WBE in understanding the link between viral surveillance in wastewater and public health, highlighting the need for its further integration into public health management.

12 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Bruna MachadoBruna Machado
Bruna Machado
KHKatharine Valéria Saraiva Hodel
Katharine Valéria Saraiva Hodel
LFLarissa Fonseca
Larissa Fonseca
VPVinícius Couto Pires
Vinícius Couto Pires
LMLuis Alberto Brêda Mascarenhas
Luis Alberto Brêda Mascarenhas
RBRoberto Badaro
Roberto Badaro
The COVID-19 pandemic has led the world to undertake the largest vaccination campaign in human history. In record time, unprecedented scientific and governmental efforts have resulted in the acquisition of immunizers utilizing different technologies (nucleotide acids, viral vectors, inactivated and protein-based vaccines). Currently, 33 vaccines have already been approved by regulatory agencies in different countries, and more than 10 billion doses have been administered worldwide. Despite the undeniable impact of vaccination on the control of the pandemic, the recurrent emergence of new variants of interest has raised new challenges. The recent viral mutations precede new outbreaks that rapidly spread at global proportions. In addition, reducing protective efficacy rates have been observed among the main authorized vaccines. Besides these issues, several other crucial issues for the appropriate combatting of the pandemic remain uncertain or under investigation. Particularly noteworthy issues include the use of vaccine-boosting strategies to increase protection; concerns related to the long-term safety of vaccines, child immunization reliability and uncommon adverse events; the persistence of the virus in society; and the transition from a pandemic to an endemic state. In this review, we describe the updated scenario regarding SARS-CoV-2 variants and COVID-19 vaccines. In addition, we outline current discussions covering COVID-19 vaccine safety and efficacy, and the future pandemic perspectives.

17 November 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Bruna MachadoBruna Machado
Bruna Machado
KHKatharine Valéria Saraiva Hodel
Katharine Valéria Saraiva Hodel
LFLarissa Fonseca
Larissa Fonseca
LMLuís Alberto Brêda Mascarenhas
Luís Alberto Brêda Mascarenhas
LALeone Peter Correia da Silva Andrade
Leone Peter Correia da Silva Andrade
RBRoberto Badaro
Roberto Badaro
In recent years, vaccine development using ribonucleic acid (RNA) has become the most promising and studied approach to produce safe and effective new vaccines, not only for prophylaxis but also as a treatment. The use of messenger RNA (mRNA) as an immunogenic has several advantages to vaccine development compared to other platforms, such as lower coast, the absence of cell cultures, and the possibility to combine different targets. During the COVID-19 pandemic, the use of mRNA as a vaccine became more relevant; two out of the four most widely applied vaccines against COVID-19 in the world are based on this platform. However, even though it presents advantages for vaccine application, mRNA technology faces several pivotal challenges to improve mRNA stability, delivery, and the potential to generate the related protein needed to induce a humoral- and T-cell-mediated immune response. The application of mRNA to vaccine development emerged as a powerful tool to fight against cancer and non-infectious and infectious diseases, for example, and represents a relevant research field for future decades. Based on these advantages, this review emphasizes mRNA and self-amplifying RNA (saRNA) for vaccine development, mainly to fight against COVID-19, together with the challenges related to this approach.

19 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KHKatharine Valéria Saraiva Hodel
Katharine Valéria Saraiva Hodel
BFBianca Fiuza
Bianca Fiuza
RCRodrigo Souza Conceição
Rodrigo Souza Conceição
AAAugusto Aleluia
Augusto Aleluia
Thassila PitangaThassila Pitanga
Thassila Pitanga
Bruna MachadoBruna Machado
Bruna Machado
Pharmacovigilance plays a central role in safeguarding public health by continuously monitoring the safety of vaccines, being critical in a climate of vaccine hesitancy, where public trust is paramount. Pharmacovigilance strategies employed to gather information on adverse events following immunization (AEFIs) include pre-registration data, media reports, clinical trials, and societal reporting. Early detection of AEFIs during clinical trials is crucial for thorough safety analysis and preventing serious reactions once vaccines are deployed. This review highlights the importance of societal reporting, encompassing contributions from community members, healthcare workers, and pharmaceutical companies. Technological advancements such as quick response (QR) codes can facilitate prompt AEFI reporting. While vaccines are demonstrably safe, the possibility of adverse events necessitates continuous post-marketing surveillance. However, underreporting remains a challenge, underscoring the critical role of public engagement in pharmacovigilance. This narrative review comprehensively examines and synthesizes key aspects of virus vaccine pharmacovigilance, with special considerations for specific population groups. We explore applicable legislation, the spectrum of AEFIs associated with major vaccines, and the unique challenges and perspectives surrounding pharmacovigilance in this domain.

26 January 2020 in Polymers
Verified
Journal Article
Open access
PDF file
KHKatharine Valéria Saraiva Hodel
Katharine Valéria Saraiva Hodel
LFLarissa Fonseca
Larissa Fonseca
ISIsa Moreira da Silva Santos
Isa Moreira da Silva Santos
JCJamile Costa Cerqueira
Jamile Costa Cerqueira
RSRaimundo Evangelista dos Santos-Júnior
Raimundo Evangelista dos Santos-Júnior
Bruna MachadoBruna Machado
Bruna Machado
Bacterial cellulose (BC) has received considerable attention due to its unique properties, including an ultrafine network structure with high purity, mechanical strength, inherent biodegradability, biocompatibility, high water-holding capacity and high crystallinity. These properties allow BC to be used in biomedical and industrial applications, such as medical product. This research investigated the production of BC by Gluconacetobacter hansenii ATCC 23769 using different carbon sources (glucose, mannitol, sucrose and xylose) at two different concentrations (25 and 50 g∙L−1). The BC produced was used to develop a biocomposite with montmorillonite (MMT), a clay mineral that possesses interesting characteristics for enhancing BC physical-chemical properties, at 0.5, 1, 2 and 3% concentrations. The resulting biocomposites were characterized in terms of their physical and barrier properties, morphologies, water-uptake capacities, and thermal stabilities. Our results show that bacteria presented higher BC yields in media with higher glucose concentrations (50 g∙L−1) after a 14-day incubation period. Additionally, the incorporation of MMT significantly improved the mechanical and thermal properties of the BC membranes. The degradation temperature of the composites was extended, and a decrease in the water holding capacity (WHC) and an improvement in the water release rate (WRR) were noted. Determining a cost-effective medium for the production of BC and the characterization of the produced composites are extremely important for the biomedical applications of BC, such as in wound dressing materials.

20 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
JRJoão Henrique de Oliveira Reis
João Henrique de Oliveira Reis
Bruna MachadoBruna Machado
Bruna Machado
GBGabriele de Abreu Barreto
Gabriele de Abreu Barreto
Jeancarlo Pereira Dos AnjosJeancarlo Pereira Dos Anjos
Jeancarlo Pereira Dos Anjos
LFLarissa Fonseca
Larissa Fonseca
JDJanice Izabel Druzian
Janice Izabel Druzian
The objective of this study was to determine the best operational conditions for obtaining red propolis extract with high antioxidant potential through supercritical fluid extraction (SFE) technology, using carbon dioxide (CO2) as the supercritical fluid and ethanol as the cosolvent. The following parameters were studied: overall extraction curve, S/F (mass of CO2/mass of sample), cosolvent percentage (0, 1, 2 and 4%) and global yield isotherms as a function of different pressures (250, 350 and 450 bar) and temperatures (31.7, 40 and 50 °C). Within the investigated parameters, the best conditions found were an S/F of 131 and the use of ethanol at the highest concentration (4% w/w), which resulted in higher extract yields and higher content of antioxidant compounds. Formononetin, the main biomarker of red propolis, was the compound found at the highest amounts in the extracts. As expected, the temperature and pressure conditions also influenced the process yield, with 350 bar and 40 °C being the best conditions for obtaining bioactive compounds from a sample of red propolis. The novel results for red propolis found in this study show that it is possible to obtain extracts with high antioxidant potential using a clean technology under the defined conditions.